- News & Features
Asking your doctor is among the best ways to find out about new treatments and clinical trials.
Hearing that my lab work is normal does not mean that my rheumatoid arthritis is not active. If I don’t...
Ever wonder what life is like for those living chronic and invisible diseases? Learn about the invisible struggles people with chronic disease face.
Higher MBDA scores yielded statistically significant associations with higher serious infection rates and significantly higher rates of heart disease.
Studies will be skewed if they examine the effects of biologics without accounting for the demographics of which patients are prescribed which medications, according to new research from Swedish scholars.
On Dec. 14, Pfizer, which makes tofacitinib (Xeljanz), announced that the FDA had approved the drug for PsA.
The introduction of biologic disease-modifying anti-rheumatic drugs are associated with a decrease in total knee replacements among RA patients.
In 2017, CreakyJoints lived up to our mantra of “bringing arthritis to its knees", by increasing support, education, advocacy, and research activities.
These findings suggest that there is a window of opportunity to treat patients with undifferentiated arthritis early, to delay subsequent progression to RA.
We surveyed 250 people and found that 59% of women with inflammatory arthritis had fewer children than they desired. Read more about the study.